TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis. [PDF]
Ther Adv Med Oncol, 2023 Tissue-agnostic indications for targeted therapies have expanded options for patients with advanced solid tumors. The Food and Drug Administration approvals of the programmed death-ligand 1 inhibitor pembrolizumab and the TRK inhibitors larotrectinib and
Medford AJ +15 more
europepmc +2 more sources
Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma. [PDF]
Sci Rep, 2021 In the last two decades, various therapies have been introduced for lung carcinoma patients, including tyrosine-kinase inhibitors for different mutations. While some of them are specific to specific tumor types, others, like NTRK1–3 fusions, are found in
Strohmeier S +5 more
europepmc +2 more sources
NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities. [PDF]
Pathol Oncol Res, 2022 Undifferentiated round cell sarcomas (URCS) of soft tissue and bone and tumours of uncertain differentiation (TUD) are commonly ascribed to a subset of neoplasms with low frequency of NTRK gene fusions.
Nozzoli F +8 more
europepmc +2 more sources
TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions. [PDF]
Int J Mol Sci, 2022 Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous malignant tumor with neuroendocrine differentiation, with a rapidly growing incidence rate, high risk of recurrence, and aggressive behavior.
Cappellesso R +20 more
europepmc +2 more sources
Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions. [PDF]
Mod Pathol, 2021 Fusions involving NTRK1 , NTRK2 , and NTRK3 are oncogenic drivers occurring in a spectrum of mesenchymal neoplasms ranging from benign to highly malignant tumors.
Brčić I +11 more
europepmc +2 more sources
LMIC-02. FREQUENCY OF NTRK FUSIONS IN PEDIATRIC LOW GRADE GLIOMAS. DATA FROM A SINGLE CENTER IN MONTERREY, MEXICO [PDF]
Neuro OncolBACKGROUND Neurotrophic tyrosine receptor kinases (NTRK 1-3)fusions have been identified in a range of pediatric cancer. Among children with cancer NTRK fusions can be detected in less than 1% of cases.
C. Leal-Cavazos +2 more
europepmc +2 more sources
NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine. [PDF]
Int J Mol Sci, 2020 In the era of precision medicine, the identification of several predictive biomarkers and the development of innovative therapies have dramatically increased the request of tests to identify specific targets on cytological or histological samples ...
Zito Marino F +9 more
europepmc +2 more sources
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. [PDF]
Am J Surg Pathol, 2018 Tropomyosin receptor kinase (Trk) inhibitors have shown high response rates in patients with tumors harboring NTRK fusions. We identified 4 NTRK fusion-positive uterine sarcomas that should be distinguished from leiomyosarcoma and undifferentiated ...
Chiang S +16 more
europepmc +2 more sources
ErbB4 Is a Potential Key Regulator of the Pathways Activated by NTRK-Fusions in Thyroid Cancer
Applied Sciences, 2022 NTRK gene fusions are drivers of tumorigenesis events that specific Trk-inhibitors can target. Current knowledge of the downstream pathways activated has been previously limited to the pathways of regulator proteins phosphorylated directly by Trk ...
Andrey Kechin +4 more
doaj +2 more sources
Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. [PDF]
Cancer Res, 2019 Oncogenic fusions involving NTRK1, NTRK2, and NTRK3 with various partners are diagnostic of infantile fibrosarcoma and secretory carcinoma yet also occur in lower frequencies across many types of malignancies. Recently, targeted small molecular inhibitor
Solomon JP, Hechtman JF.
europepmc +2 more sources